243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.
Delaloge, S Conte, P Im, S Senkus-Konefka, E Xu, B Domchek, S Masuda, N Li, W Tung, N Armstrong, Anne C
Delaloge, S
Conte, P
Im, S
Senkus-Konefka, E
Xu, B
Domchek, S
Masuda, N
Li, W
Tung, N
Armstrong, Anne C
Citations
Altmetric:
Abstract
Description
Date
2017-09
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice. 2017, 28(suppl_5): Ann Oncol